Developing Innovative Biotherapeutics driven by Unmet Medical Needs -Xiaodong Yang, MD-02/28/2012 - 8:30am

Event Information
Event Topic: 
Developing Innovative Biotherapeutics driven by Unmet Medical Needs
Event Date: 
02/28/2012 - 8:30am
Event Location: 
Fenwick & West LLP, 801 California Street, Mt View - Two-hour parking is available in the lot adjacent to Bryant Street intersection with California
Speaker Information
Event Speaker: 
Xiaodong Yang, MD
Event Speaker Title: 
President & CEO
Event Speaker Company: 
Apexigen
Event Speaker Bio: 

Dr. Xiaodong Yang

Dr. Xiaodong Yang is President and Chief Executive Officer of Apexigen which is a biopharma company focusing on development of antibody therapeutics. He has over 15 years of experience in the research and development of antibody and siRNA therapeutics. Prior to joining Apexigen, Dr. Yang was Vice President of Research and Preclinical Development at Intradigm Corporation (now Silence Therapeutics). In this role, he was responsible for overseeing the progress of company’s discovery and preclinical development of RNAi-based therapeutics. Dr. Yang began his career as a founding scientist at Abgenix (now Amgen). He was Senior Director and the head of the Oncology Therapeutic Program Team responsible for setting strategy and managing the company’s oncology portfolio. Dr. Yang was the project team leader for Vectibix® (panitumumab) and played a key role in discovery, development and BLA approval for Vectibix®. He was also in charge of managing the company’s partnerships on a number of therapeutic antibody collaboration programs.
He was an American Diabetes Association and Juvenile Diabetes Foundation postdoctoral fellow at Stanford University School of Medicine in Microbiology and Immunology, and was also trained as a research fellow at Novartis. Dr. Yang received his medical degree from Beijing Medical University and was awarded his doctorate in Immunology from University of Bern in Switzerland.

Event Details
Cost: 
$0
Event Details: 

In the current economic, financial and regulatory environment, it has become increasingly challenging to develop innovative biotherapeutics such as novel antibody-based therapeutics. Apexigen is a start-up biopharma company focusing on discovery and development of best-in-class antibody therapeutics for the treatment of cancer and inflammation. At Apexigen, we believe innovation in drug discovery and development must be driven by the needs of patients. This presentation will illustrate and discuss the opportunities and hurdles facing biopharma companies in growing their businesses and achieving the ultimate goal of delivering innovative medicines to patients.

Payment Options Dec 12th Evening Event

Attention B2DG members: You must login to your account first to see the members' early-bird admission rate.
If you are not a B2DG member or if you had missed the early-bird deadline, the registration fee is $20. Please follow these instructions to register.

We use PAYPAL to process your online payment. Print and bring a copy of your online receipt with you. If space permits, walk-ins are welcomed; please be prepared to pay $25 at the door (cash or check). There is no refund, exchange, or transfer. Thank you for your cooperation.
To register now, please select your meal preference from the pull-down menu below and enter the attendee's information. Then click on the "Pay Now" button to reach the PayPal payment page. Each attendee must be registered separately.
Make sure you enter the attendee's meal choice, name, and email address.


Meal Choice
Name of Attendee
Email Address